Compare Crispr Therapeutics AG (CRSP) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Waste Management, Inc. — how do they compare? Crispr Therapeutics AG trades at $52.9 (market cap $4.88B), while Waste Management, Inc. trades at $208.73 (market cap $83.98B). The key difference: Waste Management, Inc. is far larger — about 17.2× Crispr Therapeutics AG's market cap, and Waste Management, Inc. pays a 1.8% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Waste Management, Inc. for 130 Days on average.
| CRSP | WM | |
|---|---|---|
Market Cap | $4.88B | $83.98B |
Volume | 2,861,747 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $74.92 | $246.51 |
52-Week Low | $44.34 | $196.77 |
Typical Hold Time | 77 Days | 130 Days |
Enterprise Value | $3.30B | $106.78B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
WM trades at $208.94, up 0.51% today, with a bearish technical signal but strong fundamentals including 11.12% net income margin and 29.83% ROE. Recent earnings show beats in Q1 and Q2 2026, while Q4 2025 missed estimates. Revenue grew to $25.20B in 2025, and cash flow from operations remains robust at $6.04B. Analyst sentiment is positive with 54% buy ratings and no sell recommendations.
The outlook is supported by steady revenue growth and high profitability, but risks include elevated debt levels and competitive pressures. The stock's valuation at a P/E of 29.72 may limit near-term upside, though institutional backing and dividend payments provide stability. Investors should weigh solid cash generation against debt concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
